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Abstract
Background/aims—Varicella zoster virus
(VZV) is a causative agent in acute retinal
necrosis (ARN) syndrome. However, in
spite of aggressive antiviral therapy, clini-
cal characteristics among patients have
varied. DiVerent viral strains were exam-
ined to determine their respective role in
producing clinical characteristics. The
viral strains were also compared with
those of previously reported ones.
Methods—To diVerentiate VZV strains R1
and R5, variable regions of VZV were
amplified by nested polymerase chain
reaction (PCR) in 11 eyes of 10 patients.
Sequence analysis was also performed.
Results—Four cases had strains diverted
only at the tip of the 3' end of the R1 vari-
able region, similar to that of the H-N3
strain, which was previously reported.
Conversely, other cases were diverted to
other regions. Interestingly, some of the
latter cases showed multiple PCR prod-
ucts in the R1 region that were generated
by the truncation of either the 5' or 3' R1
region. Final visual acuities of these
patients were less than 0.2. The former
cases showed final visual acuities more
than 0.4. Only two variants were from the
R5 region. No patient had the same viral
strain as the European Dumas type.
Conclusion—These results showed that
variable VZV strains participated in ARN.
Using PCR of the R1 variable region, it
was estimated that patients with a more
fulminant type of ARN may have diverse
viruses with extensive replication in the
aVected eyes.
(Br J Ophthalmol 2000;84:193–198)
Varicella zoster virus (VZV) is a human herpes
virus that belongs to the Alphaherpesvirinae
family.1 The complete genome sequence of
VZV, which was first reported in the European
strain (Dumas) by Davison and Scott,2 com-
prises 124 884 base pairs, and is about 80×106
daltons in size.3 VZV causes chickenpox in sus-
ceptible individuals, and 95% of the popula-
tion is immune to the childhood infection.4
After reactivation from latency in the dorsal
root ganglia, VZV may also cause shingles, and
is becoming more prevalent as the average age
of the general population increases.5 The virus
may also play an important part in the cause of
acute retinal necrosis syndrome (ARN) and
related disorders. These findings have been
confirmed by direct viral detection, local
antibody production,6 and viral genome detec-
tion by polymerase chain reaction (PCR).7–10
Results of these methods have been
comparable.11 Detection of viruses and anti-
viral therapy have dramatically improved the
prognosis of patients with the disease,12 when
compared with those originally described by
Urayama and coworkers.13 However, in spite of
the same regimen of antiviral therapy, the clini-
cal course and severity of the disease diVer
widely among patients with ARN syndrome.
Some authors have reported that patients with
ARN syndrome show mild clinical appearance
and retain good visual function, while others
described patients with a more fulminant clini-
cal course and deteriorating visual function.14
One report also stated that the more fulminant
type of ARN had statistically significant
amounts of virus in the ocular fluids, in
contrast with mild cases15; however, no reports
have indicated what kinds of factors may have
influenced those findings.
Previous attempts have been made to deter-
mine VZV strains by the restriction endonucle-
ase digestion pattern, using cell culture systems
to distinguish the wild type strain from the vac-
cine strain, or as methods for an epidemiologi-
cal tool.5 16 17 However, more recently, PCR
methods have been developed to diVerentiate
VZV strains by using the repeated elements of
the VZV genome or the specific site for several
restriction enzymes, because variation in the
number of repeats has been observed over
time.4 18 19 In this report, we examined the
diVerences of the VZV strains by using PCR of
the R1 and R5 variable regions to assess if dif-




We studied 11 eyes from 10 patients from the
Miyagi prefecture, where the university medi-
cal centre is located, or just adjacent to it. We
collected vitreous or aqueous samples from
these patients (Table 1). In cases 5 and 7 (see
Figs 2 and 4), we collected samples two or
three times during follow up examination. All
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patients had demonstrated amplified VZV
genome by primers of VZV-1 and VZV-2. We
excluded patients who did not show amplified
R1 and R5 variable regions by these primers, in
spite of repeated examinations, or who refused
to receive antiviral therapy or surgical treat-
ment. All patients were well matched to the
American Uveitis Society’s criteria for the
diagnosis of ARN,20 even though severity of the
disease varied. Patients demonstrated exten-
sion of retinal exudates from I to III, according
to the classification of Matsuo et al 14 (Table 1).
Informed consent was obtained from all
subjects who participated in this study. In the
patients with bilateral infection (cases 5 and 6),
the second eye was aVected 7 days after the
first. All other patients had unilateral infection,
and no infection was observed in the second
eye during the follow up period. Cases 7, 8,
and 10 had a history of VZV dermatitis before
the onset of ARN. Case 9 underwent removal
of fibrous dysplasia of the left sphenoidal sinus
at age 9 years, and has been followed up by us
for optic atrophy of the left eye (best corrected
visual acuity was 0.1).
No patient had received antiviral treatment
before the first anterior chamber tap. All were
treated with the systemic antiviral drug aciclo-
vir, 30 mg/kg21 and a local and systemic steroid
(dexamethasone, 60 mg/day, tapered weekly)
until vitreous surgery was performed, if neces-
sary. For cases 2 and 10, we examined only the
vitreous. Case 1 had very mild focal retinal
necrosis and focal arteritis, which reacted
promptly to aciclovir and steroid therapy. The
surgical patients (10 eyes) were treated with
scleral buckling, a three port vitrectomy with
intravitreal administration of aciclovir (40
µg/ml) and dexamethasone (6 µg/ml),22 and
endophotocoagulation. None of the final visual
acuities was thought to be influenced by
secondary cataract or surgical complications.
CONDITION OF PCR
We used the same methods for PCR as
previously reported.11 Briefly, with the use of a
thermocycler (Perkin Elmer, Norwalk, CT,
USA), PCR was carried out in 50 µl of reaction
mixture containing 1 µl of the treated vitreous
or aqueous humour (described below), 20 µM
of each primer (VZV-1 and VZV-2, VZV-1R1
and VZV-1R2, and VZV-5R1 and VZV-5R2);
200 µM each of dATP, dCTP, dGTP, and
TTP; 50 mM of KCl; 10 mM of TRIS Cl (pH
8.3); 1.5 mM of MgCl2 and 0.001% gelatin;
and 2.5 units of Taq polymerase. The DNA
concentrations of the samples were adjusted
following measurement by spectrophotometry
(Ultrospec 4000, Pharmacia Biotech, Cam-
bridge). The concentrations used in the study
are shown in Table 1. There were 35 reaction
cycles. The temperature settings for PCR were
94°C for 1 minute of denaturation, 60°C for 2
minutes of annealing, and 72°C for 2 minutes
of polymerisation. For the negative control, we
performed PCR without samples under the
same conditions as described. The PCR prod-
ucts were further examined by nested primer
sets (VZV-1R3 and VZV-1R4 or VZV-5R3 and
VZV-5R4), which were designed from the









1 53/F/R 0.7 1.2 I — 11
2 36/F/L 0.3 1.2 I — 10
3 69/M/R 0.4 0.4 I — ND
4 24/M/L 0.4 1.0 IIp — 7
5 69/F/R 0.1 0.1 IIp — 11
6 69/F/L 0.1 0.6 I — 6
7 68/F/R 0.5 0.1 IIt VZV dermatitis† 9
8 81/F/R 0.1 0.2 I VZV dermatitis 10
9‡ 13/M/L NLP NLP III Fibrous dysplasia in left
sphenoidal sinus (postop)
7
10 69/F/L CF 0.04 IIp VZV dermatitis ND
11 30/F/R 0.04 LS III — 11
*Extension of retinal exudates.12 (I) Indicates exudates restricted to the area between the ora ser-
rata and vortex vein; (II) exudates between vortex vein and vascular arcades; (III) exudates beyond
vascular arcades; IIt, exudates involving the entire 360° area II; and IIp, partial degree of area II.
Visual acuity: initial/final, visual acuities when patients first consulted us and most recent. †VZV
dermatitis indicated the previous history of the presence of VZV dermatitis. ‡Patient 9 had had
surgery for fibrous dysplasia in his left sphenoid sinus and showed optic atrophy postoperatively.
Figure 1 Fundus photographs of patients 1 and 11. Mild arteritis close to the optic disc
and mid-peripheral areas are seen in patient 1. Mild retinal exudates occur at the far
periphery of the temporal region, which is not clearly visible (A). Conversely, the fundus of
case 11 shows extensive retinal exudates with retinal haemorrhages in almost all the retinal
regions except the macular area (B).
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inner sequences of VZV-1R1 and VZV-1R2 or
VZV-5R1 and VZV-5R2, respectively; 20
cycles of PCR under the same condition as
described here, except for 65°C for annealing,
were performed using 1 µl of each PCR
product.22 In each case, amplified DNA was
separated in 2% agarose gel (SeaKem, FMC
BioProducts, Rockland, ME, USA) containing
0.05 µg/ml ethidium bromide. DNA was visu-
alised with use of an ultraviolet transillumina-
tor.
PRIMERS
Primers for amplifying the R1 and R5 variable
regions of VZV genome were determined from
the sequence by Davison and Scott2 using





















The primer sets of VZV-1 and VZV-2,
VZV-1R1 and VZV-1R2, VZV-1R3 and VZV-
1R4, VZV-5R1 and VZV-5R2, and VZV-5R3
and VZV-5R4 amplified VZV genome DNA
for 126, 598, 508, 801, and 324 bp, respec-
tively, from the original sequence described by
Davison and Scott.2
PREPARATION OF VITREOUS AND AQUEOUS
HUMOUR SAMPLES
The vitreous samples were collected, as re-
ported previously,23 and were never diluted by
infusion fluid. About 100 µl of aqueous
humour was aspirated from the limbus with
use of a 27 gauge needle. An aliquot of the
sample (about 40 µl) was frozen and thawed
four times and boiled for 9 minutes at 100°C.11
One µl of this sample was added directly to the
PCR mixture.
Figure 2 The results of the PCR of the R1 variable region are shown. Each number of the upper lane indicates the patient
number, N; negative control, M; 100 base pair marker. Patients 5 and 6 represent both eyes of one patient who had bilateral
infection. Repeated aqueous taps were performed in cases 5 (5-1 and 5-2) and 7 (7-1, 7-2, and 7-3) during their follow up
examination. Exact amplification size of each PCR product in patients 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 (larger bands)
were 464, 464, 497, 497, 509, 509, 416, 464, 464, 461, and 497 base pairs, respectively.
1 2 3 4 5–25–1 6 7–1 7–2 7–3 8 9 10 11 N M
500 bp
200 bp
Figure 3 Construction of R1 variable region3 23; for each element see key. Dumas type was












Patient 7 Patient 8Patient 9Patient 10Patient 11: GGACGCGATCGACGACGA, : GGGAGAGGCGGAGGA,: GGACGCGATTGACGACGA,: GGA; : GAA: GGACGCGGCGGAGGA,
A
17
Construction of R1 variable region
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CHEMICALS
Taq polymerase was purchased from Takara
(Kyoto, Japan), and other chemicals were sup-
plied by Sigma (St Louis, MO, USA) or Wako
(Tokyo, Japan).
Results
The characteristics of all patients who partici-
pated in this study have been summarised in
Table 1. As we reported previously, final visual
acuities appeared to fall into two groups. Six
patients had final visual acuities of 0.2 or less,
and five patients had visual acuities of 0.4 or
better (Table 1). Figure 1 showed the panel of
fundus photographs for cases 1 (Fig 1A) and
11 (Fig 1B) from their initial visit to us. Case 1
had mild arteritis close to the optic disc and in
the mid-periphery, with mild retinal exudates
at the far periphery of the temporal region.
Conversely, the fundus of case 11 (Fig 1B)
showed extensive retinal exudates with retinal
haemorrhages in almost all the retinal regions
except the posterior pole.
We could amplify the VZV genome by the
primers of VZV-1 and VZV-2 in all of these
patients (data not shown). We could also
amplify the R1 variable region of VZV genome
in all the samples by nested PCR (Fig 2). We
found various sized PCR products from these
regions in our patients. Cases 1–6 showed only
one PCR product while cases 7–11 showed
multiple PCR products. Although the patient
in case 7 appeared to show only one PCR
product, sequence analysis revealed that multi-
ple PCR products were included in the first
sample (7-1 in Fig 2) (Fig 3). We also amplified
the other variable region, called R5, by the
indicated primer sets (Fig 4). We found that
the PCR products were divided into two sizes.
In spite of repeated analysis, we could not
amplify the R5 region in case 2. We also found
multiple PCR products in cases 5, 7, 8, and 9,
although they were faint.
After subcloning into the T vector, we
performed sequence analysis in the PCR prod-
ucts. The size diVerences were derived from
diVerent constructions of the repeated ele-
ments in the regions, which consisted of five
diVerent elements (A, B, C, D, and X) in R13 25
and two (A and B) in R5.26 The sequence of
each element was determined (Figs 3 and 5).
Cases 1, 2, 3, and 4, and parts of PCR products
of cases 8, 9, and 11 showed the same
construction in the R1 variable region as that
of H-N3 strain, with diversion only at the tip of
3' end—namely, ABBABBCBBDABABABX
in cases 1 and 2 and parts of case 9; ABBABB-
CBBDABABABABX in cases 3 and 4 and
parts of case 11; ABBABBCBBDABABABX’
(X’ indicate GAA instead of GGA (X) in the
last three nucleotides in the region) in case 8,
compared with the H-N3 strain ABBABB-
CBBDABABX reported by Kinoshita and
coworkers3 (Fig 3). Case 8 also had additional,
smaller PCR products, which were constructed
from extremely small amounts of R1 repeat
Figure 5 Construction of R5 variable region24; for each element see key. Dumas type was




















Figure 4 The results of PCR of the R5 variable region demonstrated two types of PCR products. The amplification sizes
were 548 (patient 4) and 436 (other patients) base pairs. The R5 variable region was never amplified in case 2, in spite of
repeated examinations. Abbreviations are the same as in Figure 2.
1 2 3 4 5–25–1 6 7–1 7–2 7–3 8 9 10 11 N M
324 bp
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elements (Fig 3). Cases 5 and 6, the patient
with bilateral ARN, had the largest and most
diverse construction of the region (Fig 3).
Cases 7, 9, 10, and 11 also showed additional
PCR products, similar to those of case 8, with
an extremely diverted arrangement (Figs 2 and
3). No patient had the same arrangement in
the R1 region as those of the European Dumas
type or H-S1, H-N3, and YS strains. The
arrangements of R5 repeat elements showed
either ABABABA in case 4 and parts of PCR
products of cases 5, 7, 8, and 9 or ABABA in
other patients. These arrangements were coin-
cidental with previously reported arrange-
ments26 (Fig 5). The arrangements of the R5
region were not as diverse as those of the R1
repeat region. The sequences flanking these
regions were completely matched to the previ-
ously reported sequences.2 There were no
sequences with more than one primer binding
site in these flanking and repeated regions.
Discussion
By using restriction endonuclease digestion,
several authors have tried to diVerentiate VZV
strains by size in variable regions.27 Especially
since the establishment of the live attenuated
VZV vaccine, which was developed in Japan,28
vesicular disease has been studied to determine
if it is due to a wild strain or a vaccine strain.5
The results were obtained through studies of in
vitro culture of the virus and endonuclease
digestion system.5 26 27 From those studies, sev-
eral portions were suspected to be diverse
among the viral strains. Five variable regions
(from R1 to 5) have been characterised so far,3
and these regions also were reported to be
stable.5 26 27 The regions from R1 to 3 were in
the open reading frames. Hawrami and
coworkers4 reported that R2, R3, and R4 loci
were not informative, having only a single VZV
specific allele. Conversely, R1 and R5 were
helpful to diVerentiate strains. However, be-
cause the methodology for clinical application
of the endonuclease analysis was so complex,
additional PCR methods have been developed
to diVerentiate the VZV strain by using
repeated elements of the VZV genome.4 19
We found the PCR method to be quick and
specific, especially if our results were compared
with those of the in vitro culture and restriction
endonuclease analysis.4 We also tried to grow
the viruses in tissue culture (cases 4, 5, 6, 8,
and 11) but failed. Several studies also stated
that only 20%–35% of strains can be isolated
from varicella or zoster vesicle for tissue
culture.4 29 These failures may have been due to
the lability of the virus, fastidious growth
requirement, or inability of some strains to
adapt to all in vitro cultures. The features of
each strain will have to be revealed through
other methods.
By using PCR of the R1 and R5 variable
regions in the VZV genome, we analysed the
VZV strain, which was detected in the ocular
fluids in patients with ARN, to see if they had
any influence on the patients’ clinical charac-
teristics. We also compared the strains with
those of previously reported ones. R1 regions
were diverse in patients with ARN syndrome,
when compared with those reported by Kino-
shita and coworkers3 and the European Dumas
type. Cases 1, 2, 3, and 4 closely resembled
strains that were diverse only at the tip of the 3'
end, similar to the H-N3 strain, which was
reported previously3—namely, the elements of
AB or ABAB were added to the 3' end of the
region. These changes were also observed in in
vitro passages in one of 14 clones by Kinoshita
and coworkers.3 As the authors discussed, the
minor diVerence may have been generated
during viral transmission between human
hosts, so the origin of these viruses may have
been same. These results also were coincident
with the previous report that R1 regions
among the VZV strains varied only at the 3'
end and that the 5' end was almost identical.
The extension of retinal exudates of these
patients were either I or IIp, when they initially
visited us, and they showed good visual
prognosis.
Conversely, other cases have had diverse R1
regions or have shown multiple PCR products
of the R1 region. When we consider the strain
type by only its longest allele, patients 8, 9, and
10 all have the same length R1 region as those
of patients 1 and 2. The results of sequence
analysis demonstrated that the smaller PCR
products in the R1 region of our patients
appeared as miniature models of the larger
PCR products, as if they had been truncated at
the 5' or 3' end. If we consider the peptide con-
structed from these variable regions, the
viruses with the smaller R1 region may have
extensively diverse function. Interestingly,
smaller PCR products of the R1 variable
region were never observed in our patients
whose final visual acuities were more than 0.4.
We also reported previously15 that patients
whose final visual acuities were less than 0.2
showed statistically significant amounts of
virus in the ocular fluids. The viruses may be
extensively replicative in aVected eyes. The
higher viral load in patients with a more flumi-
nant type of ARN may be responsible for the
appearance of artefacts by PCR. However, we
adjusted the DNA concentrations of the
samples as much as possible (Table 1). We
believe that the results were not influenced by
the DNA concentration.
We also could not exclude the possibility that
these multiple bands were derived from multi-
ple VZV strains that may have been reactivated
during the course of the disease. Hondo and
coworkers27 also reported that more than one
latent virus may have been reactivated, but only
a subset of whole viruses were recovered owing
to an ineYciency in isolating VZV from clinical
samples. The sensitive methods of nested PCR
may amplify almost all of the VZV genome in
the ocular samples, which have failed to be
amplified by any previous culture system.
As shown in Table 1, four of six patients with
final visual acuities less than 0.2, had a history
of VZV dermatitis (cases 7, 8, and 10) or
surgery of the sphenoidal sinus (case 9)
resulted in optic atrophy in the aVected eye
(Table 1). Immunosuppression may have
aVected the amount of viral replication.
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Divergences were prominent in the R1 vari-
able region when the results were compared
with those of the R5 elements. Hondo and
coworkers speculated that each component of
the R5 region was longer than that of R1 (88
and 24 in R5 and 18, 15 and 3 in R1 regions,
respectively), so the R5 region may be more
stable than the shorter R1 region. Our results
also appeared to support this theory.
The sensitivity of the primer sets of the R1
region was determined by limiting dilution
using a T vector containing the target se-
quences of VZV-1R1, VZV-1R2, VZV-1R3,
and VZV-1R4. The primer sets amplified the
VZV genome down to about 104 copies.
Conversely, the primer sets of VZV-1 and
VZV-2 amplified the VZV genome down to
6×102 copies (data not shown). Patients who
could not show amplification in the variable
regions, in spite of successful amplification by
VZV-1 and VZV-2, may be re-examined
through an arrangement of the primer prepara-
tion.
The patients in this study were from either
Miyagi prefecture or an adjacent region. If we
separate the strains using both R1 and R5 vari-
able regions in combination with the multiple
PCR products in the R1 region, almost all of
the patients in our study showed diVerent
strains. Interestingly, no patient had the same
strain as the European Dumas type or the
H-S1, H-N3, and YS strains from Japan.
Although we could distinguish no clinical
characteristics from the VZV strain, the results
suggested that patients with a more fulminant
type of ARN may have diverse virus with
extensive replication in the ocular fluids than
those with mild clinical appearance.
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ing the manuscript.
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